[HTML][HTML] Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation
P Comoli, S Basso, M Zecca, D Pagliara… - American Journal of …, 2007 - Elsevier
The treatment of Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative
disease (PTLD) after hematopoietic stem cell transplantation (HSCT) is still unsatisfactory.
We conducted a prospective trial to evaluate the impact of routine EBV surveillance and
preemptive treatment with the anti-CD20 monoclonal antibody rituximab on the development
of PTLD in pediatric recipients of extensively T-cell depleted HSCT from an HLA-
haploidentical relative. Twenty-seven patients were included in the surveillance program, 12 …
disease (PTLD) after hematopoietic stem cell transplantation (HSCT) is still unsatisfactory.
We conducted a prospective trial to evaluate the impact of routine EBV surveillance and
preemptive treatment with the anti-CD20 monoclonal antibody rituximab on the development
of PTLD in pediatric recipients of extensively T-cell depleted HSCT from an HLA-
haploidentical relative. Twenty-seven patients were included in the surveillance program, 12 …